RTW Biotech Opportunities Ltd (LSE: RTWG) has announced that Windward Bio Group AG, a private portfolio company, has priced its initial public offering on the Nasdaq Global Select Market at $17 per share, raising gross proceeds of approximately $175 million. Sanofi is concurrently investing $50 million in a private placement at the IPO price, bringing total gross proceeds to $225 million. The IPO price represents a 67% step-up to RTW Bio's prior holding value and a 77% step-up from cost, with Windward's shares closing up 68% on their first day of trading. This marks RTW Bio's tenth go-public event from its portfolio in 2026 and its 17th liquidity event year-to-date.

Key Points

  • RTW Biotech Opportunities Ltd (LSE: RTWG) — London Stock Exchange-listed life sciences investment company
  • Portfolio company Windward Bio priced its Nasdaq IPO at $17 per share, with shares closing at $28.50 on 13 November 2026, up 68% on the day
  • RTW Bio's total investment in Windward was $7.0 million; the first-day closing valuation represents a 196% step-up from cost
  • Investors may watch how the remaining portfolio progresses toward liquidity events, with Windward representing 0.8% of NAV as at 31 October 2026

Windward Bio's $175 Million Nasdaq IPO Closes at $28.50 on First Day of Trading

Windward Bio Group AG began trading on the Nasdaq Global Select Market under the ticker "WWB" on 13 November 2026, with shares closing at $28.50 — a 68% gain on the IPO price of $17. The offering comprised 10 million shares of common stock, generating gross proceeds of approximately $175 million. Sanofi's concurrent $50 million private placement at the IPO price brought total gross proceeds to $225 million. The first-day closing valuation represented a 180% step-up from RTW Bio's prior holding value as at 31 October 2026 and a 196% step-up from RTW Bio's total cost of $7.0 million.

RTW Bio's $7 Million Investment in Windward from Series A Through IPO Crossover Round

RTW Bio first committed $5.3 million to Windward in a Series A round in January 2025, before investing a further $1.7 million in Windward's $165 million Series B crossover round. Prior to the IPO uplift, Windward was valued at $7.4 million as at 31 October 2026, equating to 0.8% of RTW Bio's net asset value. The step-up in value following the IPO pricing and first-day close reflects the premium public investors are placing on differentiated late-stage biotech assets, according to the company's announcement.

Windward's Lead Programme WIN378 Targets Asthma and COPD With Long-Acting Antibody Technology

Windward Bio is a clinical-stage biotechnology company developing long-acting antibody medicines for patients with serious respiratory and dermatological diseases. Its lead programme, WIN378, is currently being studied in a Phase 2/3 trial for asthma and a Phase 2 trial for chronic obstructive pulmonary disease. The company's focus on extended dosing intervals — the announcement references the potential for twice-yearly dosing compared with monthly administration for standard-of-care biologics — is cited as a key differentiator in its product profile and a driver of investor interest at IPO.

Windward Is RTW Bio's Tenth Go-Public Event in 2026 as IPO Window Reopens

The Windward listing is RTW Bio's tenth go-public event from its portfolio in 2026, following IPOs by Aktis in January, Kailera in April, City Therapeutics in October, and Lycia in October, alongside five reverse or SPAC mergers announced or completed during the year. The announcement notes that large-cap pharmaceutical companies face a cumulative patent cliff of approximately $170 billion by 2032, increasing appetite for differentiated pipeline assets. Investors may monitor how RTW Bio's remaining private holdings progress toward liquidity as the 2026 IPO environment continues to develop.